Krystal Biotech Inc. (KRYS)
KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug
Krystal Biotech receives positive CHMP opinion recommending the approval of Vyjuvek for treating dystrophic epidermolysis bullosa in the EU.
Why Krystal Biotech (KRYS) Might be Well Poised for a Surge
Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Why Krystal Biotech, Inc. (KRYS) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Krystal Biotech (KRYS) Upgraded to Buy: Here's What You Should Know
Krystal Biotech (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus
Krystal Biotech's VYJUVEK shows strong growth, with 2025 sales expected to exceed $1B, bolstered by launches in the EU and Japan. Q4 earnings beat EPS expectations but slightly missed revenue forecasts; however, management's 2025 outlook coming catalysts drove a strong rally in shares. Key 2025 catalysts include VYJUVEK's EU and Japan launches, Phase 3 ocular DEB results, and progress in CF and lung gene therapy.
Krystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock Up
KRYS stock gains despite reporting mixed fourth-quarter results as lead drug Vyjuvek's launch in the United States shows strong uptake.
Krystal Biotech, Inc. (KRYS) Q4 2024 Earnings Call Transcript
Krystal Biotech, Inc. (NASDAQ:KRYS ) Q4 2024 Results Conference Call February 19, 2025 8:30 AM ET Company Participants Stephane Paquette - VP, Corporate Development Krish Krishnan - Chairman and CEO Jennifer McDonough - SVP, Patient Access, Analytics and Operations Christine Wilson - SVP and Head, U.S. Sales and Marketing Suma Krishnan - President, Research and Development Kate Romano - CAO Conference Call Participants Alec Stranahan - BOA Ritu Baral - TD Cowen Gavin Clark-Gartner - Evercore ISI Sami Corwin - William Blair Ry Forseth - Guggenheim Josh Schimmer - Cantor Andrea Newkirk - Goldman Sachs Operator Thank you for standing by, and welcome to the Krystal Biotech Q4 2024 Earnings Call. At this time, all participants are on a listen-only mode.
Is the Options Market Predicting a Spike in Krystal Biotech (KRYS) Stock?
Investors need to pay close attention to Krystal Biotech (KRYS) stock based on the movements in the options market lately.
Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy
Krystal Biotech's VYJUVEK, a groundbreaking gene therapy for DEB, achieved $83.8M in Q3 2024 sales, doubling from Q4 2023. Trading at 57x 2024 earnings, Krystal's stock appears expensive but is projected to double earnings by 2025. With imminent EU and Japanese market expansion, Krystal seems poised to outperform analyst's expectations for growth.
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707
Krystal Biotech reports initial data from a phase I/II study showing therapeutic benefit in NSCLC patients treated with its immunotherapy candidate, KB707.
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408
Krystal Biotech posts initial clinical updates on its two pipeline candidates, KB407 and KB408, which are being developed to treat rare respiratory diseases.
Why Is Krystal Biotech (KRYS) Up 6.6% Since Last Earnings Report?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
